Navigation Links
InVitria Successfully Completes Beta Testing and Announces Commercial Launch of Optiferrin for Mammalian Cell Culture
Date:9/17/2009


Optiferrin shown to provide superior performance in cell culture and addresses the need for animal-free transferrin in many applications including Stem Cells, Primary Cells, Hybridoma Cells and Chinese Hamster Ovary (CHO) cells.

Fort Collins, CO September 17, 2009 / b3c newswire / C InVitria today announced the launch of Optiferrin, a high performance, well-defined and animal-free recombinant transferrin for use in mammalian cell culture. Optiferrin is a cell culture supplement which supports cell growth by regulating the amount of iron transported to the cell. Since iron is required for healthy cell culture performance, it is a critical component to reach optimal performance.

Optiferrin has undergone extensive testing by our beta customers since June 2009. They have formulated Optiferrin into their cell culture media to provide maximum performance and they liked their results. We are delighted to be able to bring this sort of value to our customers through innovations like Optiferrin, said Scott Deeter, President & CEO of InVitria.

Transferrin is natures way to deliver iron in a non-toxic manner, said Dr. Steve Pettit, InVitrias Director of Cell Culture Development. Our product development, along with beta customer results, confirmed that Optiferrin delivered optimal performance without any cell damage. This alleviates customers concerns about animal-origin infectious contaminants or the headaches caused by addition of elemental iron and iron chelators in cell culture media, said Dr. Pettit.

Optiferrin is a complimentary product to InVitrias other cell culture supplement products, which include Cellastim, Lacromin, Zap-CHO and Zap-Hybridoma.



About InVitria - www.InVitria.com
InVitria develops, manufactures and markets a portfolio of high performance and well defined cell culture media components and reagents used in bioprocessing, biopharmaceutical formulation, stem cell & regenerative medicine, life science research, medical devices and diagnostics.

For more information about InVitrias product line, contact us at info@InVitria.com or call 1-800-916-8311.


'/>"/>
b3c newswire

Related biology news :

1. InVitria Sponsors ESACT 2009 in Dublin, Ireland
2. InVitria to Unveil Powerful Cell Culture Media Component ZAP-CHO
3. InVitria Announces Launch of Recombinant Albumin for Diagnostics
4. UOG scientists successfully compete for research grants
5. McGill/JGH researchers successfully reverse multiple sclerosis in animals
6. Funxional successfully completes initial clinical trial of FX125L, an anti-inflammatory drug with a novel mechanism of action
7. In troubled economic times, BioSquare 2009 successfully serves as business and innovation starter
8. Salk researchers successfully reprogram keratinocytes attached to a single hair
9. Model successfully predicts large river system fish diversity
10. Scientists successfully treat new mouse model of inflammatory bowel disease
11. Researchers successfully simulate photosynthesis and design a better leaf
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/20/2016)... and GENEVA, Dec, 20, 2016   Valencell ... sensor technology, and STMicroelectronics (NYSE: STM), a ... of electronics applications, announced today the launch of ... for biometric wearables that includes ST,s compact ... Valencell,s Benchmark™ biometric sensor system. Together, SensorTile ...
(Date:12/16/2016)... --  IdentyTechSolutions America LLC , a leading provider ... a cutting-edge manufacturer of software and hardware security ... integrated solutions that comprise IDT biometric readers and ... IdentyTech,s customers with combined physical identification and anti-tailgating ... theft. "We are proud to use ...
(Date:12/16/2016)... , Dec. 16, 2016 The global wearable medical device ... billion by 2021 from USD 5.31 billion in 2016, at a ... ... driven by technological advancements in medical devices, launch of a growing ... for wireless connectivity among healthcare providers, and increasing focus on physical ...
Breaking Biology News(10 mins):
(Date:1/21/2017)... NY (PRWEB) , ... January 20, 2017 , ... Nipro ... a Joint Venture (JV) under which Nipro will receive exclusive marketing and sales rights ... to establish best practices for hemodialysis patients in Japan, the new Nipro - Transonic ...
(Date:1/21/2017)... 2017 Interpace Diagnostics Group, Inc. (NASDAQ: ... clinically useful molecular diagnostic tests and pathology services, ... securities purchase agreement with three  institutional investors to ... stock in a registered direct offering.  In a ... sell to the same investors warrants to purchase ...
(Date:1/21/2017)... Kan. , Jan. 20, 2017 Aratana ... therapeutics company focused on the licensing, development and commercialization ... Animal Pharm,s Best Company in North ... granted the award based on the FDA ... (grapiprant tablets), ENTYCE ® (capromorelin oral solution) ...
(Date:1/20/2017)... ... 2017 , ... The two newest companies to join the University City Science ... out from The Wistar Institute, and Sanguis, launched by a trio of students from ... , Vironika is developing a treatment for a chronic viral infection and its associated ...
Breaking Biology Technology: